| 992 | 13 | 35 |
| 下载次数 | 被引频次 | 阅读次数 |
肺癌是中国最常见的原发性恶性肿瘤，主要分为小细胞肺癌和非小细胞肺癌(NSCLC),后者占85%。本研究探讨了NSCLC的病因、治疗策略及靶向治疗的最新进展。对靶向治疗中针对特定基因突变患者应用靶向药物抑制剂的效果进行了分析，结果显示分子靶向治疗可显著延长患者的生存期。因此，个体化治疗已逐渐成为肺癌管理的新模式，突出了分子靶向治疗的重要性，为肺癌的临床治疗提供了新的方向和依据。
Abstract：Lung cancer is the most prevalent primary malignant tumor in China, which is mainly categorized into small cell lung cancer and non-small cell lung cancer(NSCLC),with NSCLC accounting for 85%.This study delves into the etiology, treatment strategies, and the latest progress in targeted therapy for NSCLC.Through an analysis of the efficacy of targeted drug inhibitors administered to patients with specific gene mutations in the context of targeted therapy, it has been demonstrated that molecular targeted therapy can significantly prolong the survival time of patients.Consequently, personalized treatment has gradually emerged as a new paradigm for lung cancer management, underlining the significance of molecular targeted therapy and offering novel directions and a basis for the clinical treatment of lung cancer.
[1] 郑荣寿，陈茹，韩冰峰，等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2024,46(3):221-231.
[2] Guo H,Zhang J,Qin C,et al.Biomarker-Targeted therapies in non-small cell lung cancer:current status and perspectives[J].Cells,2022,11(20):3200-3223.
[3] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[4] Thai AA,Solomon BJ,Sequist LV,et al.Lung cancer[J].The Lancet,2021,398(10 299):535-554.
[5] Alduais Y,Zhang H,Fan F,et al.Non-small cell lung cancer(NSCLC):A review of risk factors,diagnosis,and treatment[J].Medicine(Baltimore),2023,102(8):e32 899-e32 903.
[6] Deb D,Moore AC,Roy UB.The 2021 Global lung cancer therapy landscape[J].J Thorac Oncol,2022,17(7):931-936.
[7] Roskoski R Jr.Properties of FDA-approved small molecule protein kinase inhibitors:A2023 update[J].Pharmacol Res,2023,187:106 552.
[8] Levantini E,Maroni G,Del Re M,et al.EGFR signaling pathway as therapeutic target in human cancers[J].Semin Cancer Biol,2022,85:253-275.
[9] Da Cunha Santos G,Shepherd FA,Tsao MS.EGFR mutations and lung cancer[J].Annu Rev Pathol,2011,6:49-69.
[10] Herbst RS,Morgensztern D,Boshoff C.The biology and management of non-small cell lung cancer[J].Nature,2018,553(7689):446-454.
[11] Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.
[12] 徐明翠，王剑，阳韬.晚期非小细胞肺癌靶向治疗进展[J].临床肺科杂志，2023,28(1):108-116.
[13] De Leeuw SP,de Bruijn P,Koolen SLW,et al.Quantitation of osimertinib,alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS[J].J Pharm Biomed Anal,2023,225:115 233-115 340.
[14] Wang M,Fan Y,Sun M,et al.Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation(WU-KONG6):single-arm,open-label,multicentre,phase 2 trial[J].Lancet Respir Med,2024,12(3):217-224.
[15] Scarpino S,Rampioni Vinciguerra GL,Di Napoli A,et al.High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adoloscents and young adults[J].Lung Cancer,2016,97:95-98.
[16] Song P,Zhang F,Li Y,et al.Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer[J].Cancer Med,2019,8(4):1551-1557.
[17] Blackhall F,Ross Camidge D,Shaw AT,et al.Final results of the large-scale multinational trial PROFILE 1005:efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer[J].ESMO Open,2017,2(3):e000219-e000228.
[18] Shaw AT,Kim DW,Nakagawa K,et al.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J].N Engl J Med,2013,368(25):2385-2394.
[19] Ahn MJ,Kim HR,Yang JCH,et al.Efficacy and safety of brigatinib compared with crizotinib in asian vs.non-asian patients with locally advanced or metastatic ALK-Inhibitor-Naive ALK+ non-small cell lung cancer:final results from the phase Ⅲ ALTA-1L study[J].Clin Lung Cancer,2022,23(8):720-730.
[20] Solomon BJ,Bauer TM,Mok TSK,et al.Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced,ALK-positive non-small-cell lung cancer:updated analysis of data from the phase 3,randomised,open-label CROWN study[J].Lancet Respir Med,2023,11(4):354-366.
[21] Solomon BJ,Besse B,Bauer TM,et al.Lorlatinib in patients with ALK-positive non-small-cell lung cancer:results from a global phase 2 study[J].Lancet Oncol,2018,19(12):1654-1667.
[22] Rikova K,Guo A,Zeng Q,et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J].Cell,2007,131(6):1190-1203.
[23] Bergethon K,Shaw AT,Ou SH,et al.ROS1 rearrangements define a unique molecular class of lung cancers[J].J Clin Oncol,2012,30(8):863-870.
[24] Drilon A,Siena S,Dziadziuszko R,et al.Entrectinib in ROS1 fusion-positive non-small-cell lung cancer:integrated analysis of three phase 1-2 trials[J].Lancet Oncol,2020,21(2):261-270.
[25] Drilon A,Camidge DR,Lin JJ,et al.Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer[J].N Engl J Med,2024,390(2):118-131.
[26] Mitiushkina NV,Kholmatov MM,Tiurin VI,et al.Comparative analysisof expression of mutant and wild-type alleles is essential for reliable PCR-based detection of MET exon 14 skipping[J].Biochimie,2019,165:267-274.
[27] Schrock AB,Frampton GM,Suh J,et al.Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations[J].J Thorac Oncol,2016,11(9):1493-1502.
[28] Michaels E,Bestvina CM.Meeting an un-MET need:Targeting MET in non-small cell lung cancer[J].Front Oncol,2022,12:1 004 198-1 004 298.
[29] Vansteenkiste JF,Van DE,Kerkhove C,et al.Capmatinib for the treatment of non-small cell lung cancer[J].Expert Rev Anticancer Ther,2019,19(8):659-671.
[30] Wolf J,Garon EB,Groen HJM,et al.Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC:Results from the GEOMETRY mono-1 study[J].Eur J Cancer,2023,183:98-108.
[31] Mazieres J,Paik PK,Garassino MC,et al.Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer:long-term follow-up of the VISION phase 2 nonrandomized clinical trial[J].JAMA Oncol,2023,9(9):1260-1266.
[32] Ren S,Wang J,Ying J,et al.Consensus for HER2 alterations testing in non-small-cell lung cancer[J].ESMO Open,2022,7(1):100 395-100 408.
[33] Pillai RN,Behera M,Berry LD,et al.HER2 mutations in lung adenocarcinomas:A report from the lung cancer mutation consortium[J].Cancer,2017,123(21):4099-4105.
[34] Vathiotis IA,Bafaloukos D,Syrigos KN,et al.Evolving treatment landscape of HER2-mutant non-small cell lung cancer:trastuzumab deruxtecan and beyond[J].Cancers(Basel),2023,15(4):1286-1297.
[35] Nützinger J,Bum Lee J,Li Low J,et al.Management of HER2 alterations in non-small cell lung cancer-the past,present,and future[J].Lung Cancer,2023,186:107 385-107 399.
[36] Goto K,Goto Y,Kubo T,et al.Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer:primary results from the randomized,phase Ⅱ DESTINY-Lung02 trial[J].J Clin Oncol,2023,41(31):4852-4863.
[37] Puri M,Gawri K,Dawar R.Therapeutic strategies for BRAF mutation in non-small cell lung cancer:a review[J].Front Oncol,2023,13:1 141 876-1 141 886.
[38] Odogwu L,Mathieu L,Blumenthal G,et al.FDA approval summary:dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations[J].Oncologist,2018,23(6):740-745.
[39] Santarpia M,Ciappina G,Spagnolo CC,et al.Targeted therapies for KRAS-mutant non-small cell lung cancer:from preclinical studies to clinical development-a narrative review[J].Transl Lung Cancer Res,2023,12(2):346-368.
[40] Ceddia S,Landi L,Cappuzzo F.KRAS-mutant non-small-cell lung cancer:from past efforts to future challenges[J].Int J Mol Sci,2022,23(16):9391-9405.
[41] O'Sullivan E,Keogh A,Henderson B,et al.Treatment strategies for KRAS-Mutated non-small-cell lung cancer[J].Cancers(Basel),2023,15(6):1635-1652.
[42] Ostrem JM,Peters U,Sos ML,et al.K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions[J].Nature,2013,503(7477):548-551.
[43] 李青芸，刘晓雯，邓昊，等.靶向Ras信号通路抑制剂在肿瘤治疗中的研究进展[J].中国细胞生物学学报，2022,44(3):469-476.
[44] Skoulidis F,Li BT,Dy GK,et al.Sotorasib for lung cancers with KRAS p.G12C mutation[J].N Engl J Med,2021,384(25):2371-2381.
[45] J?nne PA,Riely GJ,Gadgeel SM,et al.Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation[J].N Engl J Med,2022,387(2):120-131.
[46] Ou SI,Janne PA,Leal TA,et al.First-in-Human phase I/IB dose-finding study of adagrasib(MRTX849) in patients with advanced KRASG12C solid tumors(KRYSTAL-1)[J].J Clin Oncol,2022,40(23):2530-2538.
[47] De SK.First approval of adagrasib for the treatment of non-small cell lung cancer harboring a KRASG12C mutation[J].Curr Med Chem,2024,31(3):266-272.
[48] Wang X,Allen S,Blake JF,et al.Identification of MRTX1133,a noncovalent,potent,and selective KRASG12D Inhibitor[J].J Med Chem,2022,65(4):3123-3133.
基本信息:
DOI：10.16846/j.issn.1004-3101.2024.06.015
中图分类号:R734.2
引用信息:
[1]马靖潇,马春强,范雯雯,等.非小细胞肺癌的靶向治疗现状与进展[J].山东第二医科大学学报,2024,46(06):464-470.DOI:10.16846/j.issn.1004-3101.2024.06.015.
基金信息:
潍坊市科技发展计划项目(项目编号：2023YX039)
2024-12-15
2024-12-15